Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-10-04-Speech-4-180"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2001-10-04"^^xsd:date2
dcterms:Is Part Of	lp_eu:Patenting of human genes2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20011004.9.4-180"2
lpv:hasSubsequent	lp_eu:2001-10-04-Speech-4-1812
lpv:speaker	lp:Ria Oomen-ruijten2
lpv:spokenAs	member; Delegation for relations with South Africa (1999-10-06--2002-01-14)3 vice-chair; Temporary committee on human genetics and other new technologies in modern medicine (2001-01-16--2001-11-29)3 member; EPP-ED (1999-07-20--2004-07-19)3 vice-chair; Committee on the Environment, Public Health and Consumer Policy (1999-09-22--2002-01-14)3 substitute; EMPL (1999-07-21--2002-01-14)3 substitute; Committee on Women's Rights and Equal Opportunities (1999-07-20--2002-01-14)3 unknown; Christen Democratisch Appèl (1999-07-20--2004-07-19)3 substitute; Committee on Legal Affairs and the Internal Market (1999-11-04--2002-01-14)3
lpv:translated text	"Mr President, I regret that I must remain seated. On 30 March last year, Parliament declared that people and their genes or cells in a natural environment cannot be patented. However, if a patent is granted to Myriad Genetics, this will create a monopoly situation for one particular company. This means that there is a danger that certain genetic tests and some of the DNA diagnostic tests in Europe will be commercialised. Three applications for patents on sequences and applications of a breast cancer gene have now been accepted by the European Patent Office. Applications from Myriad for patents on the BRCA2 gene are still being processed. If these patents are awarded, this US company will have a monopoly on the BRCA gene and consequently on the DNA test. This means that abnormalities in patients from families with a history of breast cancer and ovarian cancer will only be able to be detected with this American test. If Myriad is going to use a similar system in Europe to the one it uses in the United States, the samples from all future laboratory tests will have to be sent to the United States, which will also be very expensive if the analyses have to be done there. This means that there is a danger that a monopoly may be created, which will put the quality of European diagnostics at risk. It also means that the availability of data for analysis purposes and the development of new diagnostic applications in our own molecular and testing laboratories will be limited, which will push up the cost of breast cancer screening and therefore of health insurance. Not only Parliament but also everyone in society who is involved in this has registered objections in this regard. We therefore ask for this monopoly position, which is in nobody's interest, to be opposed and the patent application to be rejected."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph